Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 4/20 | 0.50 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | DRD5 | P21918 | 2/20 | 0.50 |
| ▸ | HRH2 | P25021 | 2/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 2/20 | 0.50 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14610747 | 1.00 | FKBP1A (0.50) | FKBP1ACACNA1FDRD4DRD5HRH2 | |
| SCHEMBL10024995 | 0.82 | FKBP1A (0.50) | FKBP1ACACNA1FDRD4DRD5HRH2 | |
| SCHEMBL14610742 | 0.81 | HTT (0.42) | CACNA1FDRD4DRD5HRH2ADRA1D | |
| SCHEMBL523236 | 0.81 | HTT (0.42) | CACNA1FDRD4DRD5HRH2ADRA1D | |
| SCHEMBL523656 | 0.78 | KDM4E (0.56) | FKBP1ACACNA1FDRD4DRD5HRH2 | |
| SCHEMBL524458 | 0.78 | KDM4E (0.56) | FKBP1ACACNA1FDRD4DRD5HRH2 | |
| SCHEMBL524333 | 0.78 | KDM4E (0.56) | FKBP1ACACNA1FDRD4DRD5HRH2 | |
| SCHEMBL5434964 | 0.76 | NAAA (0.42) | CACNA1FDRD4DRD5HRH2ADRA1D | |
| SCHEMBL21218202 | 0.75 | FKBP1A (0.55) | FKBP1AMEN1KMT2ANPSR1GRM5 | |
| SCHEMBL524775 | 0.75 | SLC6A3 (0.38) | CACNA1FDRD4DRD5HRH2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994520-B2 | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe | MYLAN LABORATORIES LIMITED (IN) | 2018-06-12 | — | — | US | disclosed |
| US-20160280642-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MYLAN LABORATORIES LIMITED (IN) | 2016-09-29 | — | — | US | disclosed |
| US-9388440-B2 | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe | MYLAN LABORATORIES LIMITED (IN) | 2016-07-12 | — | — | US | disclosed |
| EP-2414529-A2 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | Matrix Laboratories Ltd (IN) | 2012-02-08 | — | — | EP | disclosed |
| US-20120028316-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MATRIX PHARMACORP PRIVATE LIMITED (IN) | 2012-02-02 | — | — | US | disclosed |
| WO-2010113175-A2 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | MATRIX LABORATORIES LTD (IN) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028316-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | CES1, CMA1, CYP51A1 | FKBP1A 1927/4885CACNA1F 2291/4885DRD4 1248/4885 |
| US-20160280642-A1 | ENZYMATIC PROCESS FOR THE PREPARATION OF (S)-5-(4-FLUORO-PHENYL)-5-HYDROXY- 1MORPHOLIN-4-YL-PENTAN-1-ONE, AN INTERMEDIATE OF EZETIMIBE AND FURTHER CONVERSION TO EZETIMIBE | TPSD1, PCSK9, PEPD | FKBP1A 2289/4885CACNA1F 2397/4885DRD4 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.